New Mexico is currently home to 412 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Albuquerque, Santa Fe, Las Cruces and Farmington. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Biomarker and Edema Attenuation in IntraCerebral Hemorrhage (BEACH)
NCT05020535
Recruiting
This first-in-patient phase 2a pilot study will assess the safety and tolerability of MW01-6-189WH (hereafter called MW189) in patients with Intracerebral Hemorrhage (ICH).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/09/2024
Locations: University of New Mexico, Albuquerque, New Mexico
Conditions: Intracerebral Hemorrhage
Register for Updates
Brain Oxygen Optimization in Severe TBI, Phase 3
NCT03754114
Recruiting
BOOST3 is a randomized clinical trial to determine the comparative effectiveness of two strategies for monitoring and treating patients with traumatic brain injury (TBI) in the intensive care unit (ICU). The study will determine the safety and efficacy of a strategy guided by treatment goals based on both intracranial pressure (ICP) and brain tissue oxygen (PbtO2) as compared to a strategy guided by treatment goals based on ICP monitoring alone. Both of these alternative strategies are used in s... Read More
Gender:
ALL
Ages:
14 years and above
Trial Updated:
12/06/2024
Locations: University of New Mexico Hospital, Albuquerque, New Mexico
Conditions: Brain Injuries, Traumatic
Register for Updates
Vafseo Outcomes In-Center Experience
NCT06520826
Recruiting
This trial is an investigator-initiated, multi-center, randomized (1:1), open-label, active-controlled, pragmatic study of the safety of vadadustat administered three times per week for the treatment of anemia in in-center hemodialysis patients with End Stage Kidney Disease (ESKD). This study will obtain long-term safety data in a large sample of subjects receiving in-center hemodialysis to support adoption of three times per week vadadustat dosing.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/05/2024
Locations: US Renal Care - Gallup, Gallup, New Mexico
Conditions: Anemia of Chronic Kidney Disease
Register for Updates
4D-150 in Patients With Diabetic Macular Edema
NCT05930561
Recruiting
Phase 2 randomized, active-controlled, double-masked, dose-ranging trial in adults with Diabetic Macular Edema (DME).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/03/2024
Locations: Vision Research Center Eye Associates of New Mexico, Albuquerque, New Mexico
Conditions: Diabetic Macular Edema, Diabetic Retinopathy
Register for Updates
A 52-Week Study to Learn About the Safety and Effects of Ritlecitinib in Participants With Nonsegmental Vitiligo
NCT06163326
Recruiting
This study is to evaluate how safe and effective ritlecitinib is in participants with non-segmental vitiligo (NSV). Ritlecitinib is studied in patients with non-segmental vitiligo. Vitiligo is a chronic acquired depigmentation disorder characterized by well-defined pale white patches of skin. Non-segmental vitiligo is an autoimmune disorder and is the focus of this study. The study will show: * if the repigmentation (the recovery of pigmentation) achieved in study B7981040 (also called the "p... Read More
Gender:
ALL
Ages:
12 years and above
Trial Updated:
12/02/2024
Locations: University of New Mexico Health Sciences Center, Albuquerque, New Mexico
Conditions: Vitiligo
Register for Updates
Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma
NCT03860883
Recruiting
Patients with a primary invasive melanoma are recommended to undergo excision of the primary lesion with a wide margin. There is evidence that less radical margins of excision may be just as safe. This is a randomised controlled trial of 1 cm versus 2 cm margin of excision of the primary lesion for adult patients with stage II primary invasive cutaneous melanomas (AJCC 8th edition) to determine differences in disease-free survival. A reduction in margins is expected to improve patient quality of... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/25/2024
Locations: Lovelace Medical Centre-Saint Joseph Square, Albuquerque, New Mexico
Conditions: Cutaneous Melanoma, Stage II
Register for Updates
Safety and Preliminary Efficacy of OBT076 in Recurrent/Metastatic CD205+ Solid Tumors
NCT04064359
Recruiting
The purpose of this study is to evaluate OBT076, which is a drug that combines an antibody with an anti-cancer drug. This class of drugs are called Antibody-Drug Conjugates (ADC). Antibodies are normally produced in the human body by the immune system to fight infections but can be designed to target cancer cells and deliver an anti-cancer drug. OBT076 is composed of an antibody that targets the CD205 protein on cancer cells and delivers an anti-cancer drug which can kill them. OBT076 is an "Inv... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/22/2024
Locations: Quantum Santa Fe, Santa Fe, New Mexico
Conditions: Solid Tumor
Register for Updates
Resistance Training for the Improvement of Glycemic Control in Prediabetes
NCT06697756
Recruiting
The purpose of this research is to study the effects of resistance exercise training with different degrees of effort on your glucose responses (what we call glycemic control) and psychological responses.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
11/19/2024
Locations: UNM Exercise Physiology Lab, Albuquerque, New Mexico
Conditions: Prediabetes (Insulin Resistance, Impaired Glucose Tolerance)
Register for Updates
A Study of ZN-c3 in Women With Recurrent or Persistent Uterine Serous Carcinoma
NCT04814108
Recruiting
This is a Phase 2 study to evaluate the clinical activity and safety of ZN-c3 (azenosertib) in adult women with recurrent or persistent uterine serous carcinoma (USC).
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
11/19/2024
Locations: Optimum Clinical Research Group- Women's Oncology, Albuquerque, New Mexico
Conditions: Uterine Serous Carcinoma
Register for Updates
Mindfulness for Alcohol Abusing Offenders
NCT03883646
Recruiting
Over half of state and federal prisoners meet clinical criteria for alcohol abuse or dependence, and after release from prison, over three-quarters of offenders are re-arrested within five years. Thus, there is a critical need for more effective interventions that could help disrupt this insidious cycle of alcohol abuse, criminal behavior, and incarceration. This project will support the development and evaluation of a mindfulness intervention for female prison inmates that will target key neuro... Read More
Gender:
FEMALE
Ages:
Between 18 years and 65 years
Trial Updated:
11/18/2024
Locations: The Mind Research Network, Albuquerque, New Mexico
Conditions: Alcohol Abuse, Criminal Behavior
Register for Updates
Eye Recovery Automation for Post Injury Dysfunction (iRAPID)
NCT06105892
Recruiting
This study will test a portable virtual reality (VR) system with integrated eye tracking called Virtual Eye Rotation Vision Exercises (VERVE). The proposed VERVE platform will deliver vergence therapy in an automated manner. This research will involve 30 non-traumatic brain injury (TBI) binocularly normal (BNC) Veterans and 50 post-traumatic convergence insufficiency (PTCI) Veterans who will undergo Active and Sham therapy (equally divided groups) to determine the effectiveness of VERVE vergence... Read More
Gender:
ALL
Ages:
Between 18 years and 40 years
Trial Updated:
11/14/2024
Locations: New Mexico VA Health Care System, Albuquerque, New Mexico
Conditions: Convergence Insufficiency, Traumatic Brain Injury, Concussion, Mild
Register for Updates
Outcomes of Clareon PanOptix in Patients With Prior Myopic Refractive Surgery
NCT06555289
Recruiting
This study is a Single center, single arm, prospective, observational study of clinical outcomes following bilateral cataract surgery and Clareon PanOptix implantation. Subjects will be assessed preoperatively, and at 1 and 3 months postoperatively. Clinical evaluations will include administration of the QUVID and IOLSAT questionnaires, manifest refraction, topography, as well as measurement of visual acuities at distance, intermediate, and near.
Gender:
ALL
Ages:
45 years and above
Trial Updated:
11/05/2024
Locations: Juliette Eye Institute Research Center, Albuquerque, New Mexico
Conditions: Cataract
Register for Updates